Generatlized Anxiety Disorder

Current Location

49 Generatlized Anxiety Disorder Trials Near You

Power is an online platform that helps thousands of Generatlized Anxiety Disorder patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

ABBV-932 for Generalized Anxiety Disorder

Columbus, Ohio
Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess how safe and effective ABBV-932 is when added to the antidepressant therapies in adult participants with GAD who have had an inadequate response ADTs. ABBV-932 is an investigational drug being developed for the adjunctive treatment of GAD. Participants will be randomly assigned to receive ABBV-932 or Placebo in addition to their currently prescribed ADTs. There is 1 in 3 chance of participants assigned to Placebo. Approximately 315 adult participants with GAD and inadequate response to ADTs will be enrolled in approximately 50 sites in the United States and Puerto Rico. Participants will receive oral capsules of ABBV-932 or matching placebo in addition to their prescribed ADT for 6 weeks and then will be followed for an additional 4 week follow-up period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Stay on current meds

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65

315 Participants Needed

Combination Therapy for Anxiety Disorders

Cincinnati, Ohio
Pediatric onset anxiety disorders (generalized anxiety, social anxiety, separation anxiety) are highly prevalent, and if untreated, are impairing into adolescence and adulthood. In the largest comparative efficacy study remission occurred in about 65% of children and adolescents treated with a combination of a selective serotonin reuptake inhibitors (SSRI) and cognitive behavioral therapy (CBT). In contrast, CBT without an SSRI achieved remission in 35% of children at 3 months and 45% at 6 months-a 30% and 20% difference, respectively. Despite the difference in remission rates, CBT alone is the preferred treatment of most patients and families. Lack of awareness of the significant difference in remission rates and concerns about medication side effects may drive patient and family preference even though SSRIs have a positive safety profile. Critiques of CBT in the above study suggest that CBT was not as effective as it could be due to short treatment duration, restricted family involvement and limited exposure sessions. Would the combination of CBT and an SSRI still be superior to CBT only, if CBT was of longer duration, and included more family involvement and exposure sessions? In the Partners in Care for Anxious Youth (PCAY) study, children and adolescents with an anxiety disorder ages 7-17 years followed in pediatric primary care clinics affiliated with three institution: Lurie Children's Hospital of Chicago, University of California Los Angeles and University of Cincinnati will be randomized to one of two treatment arms; either CBT only or CBT combined with an SSRI (either fluoxetine, sertraline, or escitalopram). CBT in PCAY will be 6 months in duration and include more family involvement, and more exposure opportunities than past trials. The 6-month acute treatment phase will be followed by 6 months of followup. The primary outcome will be anxiety symptom remission and reduction in impairment over 6 and 12-months.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:7 - 17

468 Participants Needed

Power Preferred

SEP-363856 for Generalized Anxiety Disorder

North Canton, Ohio
This Phase 2/3 clinical trial is designed to evaluate SEP-363856 for Generalized Anxiety Disorder
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:18 - 65

434 Participants Needed

ITI-1284 for Generalized Anxiety Disorder

North Canton, Ohio
This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo as adjunctive therapy to GAD treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD who have an inadequate response to ongoing GAD treatment.
Stay on current meds

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

705 Participants Needed

Anxiety Management for Anxiety Disorders

Muncie, Indiana
The goal of this research is to compare the benefits and risks of three anxiety treatments that are pragmatic, graduated in the level of resource intensity, and have demonstrated efficacy and feasibility for real world adoption.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

375 Participants Needed

Neurofeedback for Anxiety Disorders

Ann Arbor, Michigan
This study seeks to understand emotion regulation in those with anxiety using real-time functional magnetic resonance imaging neurofeedback, a tool that allows individuals to control brain activity. The goal of this project is to understand how receiving feedback about one's own brain activity relates to emotion regulation ability. This work will help the study team understand the brain areas involved in emotion regulation and could lay the groundwork to test if psychotherapy outcomes can be enhanced using neurofeedback. The study hypotheses include: * Participants receiving veritable-Neurofeedback (NF) will show a greater activation increase in the prefrontal cortex (PFC) compared to sham-NF * Participants receiving veritable-NF will show greater cognitive reappraisal (CR) ability compared to those receiving sham-NF * Prefrontal cortex activation will positively correlate with CR ability
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 55

18 Participants Needed

Neurofeedback for Anxiety

Ann Arbor, Michigan
This study seeks to understand emotion regulation in those with young adults with anxiety using real-time functional magnetic resonance imaging neurofeedback, a tool that allows individuals to control brain activity. The goal of this project is to understand how receiving feedback about one's own brain activity relates to emotion regulation ability. This work will help the study team understand the brain areas involved in emotion regulation and could lay the groundwork to test if psychotherapy outcomes can be enhanced using neurofeedback. The study hypotheses include: * Participants receiving veritable-Neurofeedback (NF) will show a greater activation increases in the prefrontal cortex (PFC) compared to sham-NF * Participants receiving veritable-NF will show greater cognitive reappraisal (CR) ability compared to those receiving sham-NF * PFC activation will positively correlate with CR ability
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 24

110 Participants Needed

Text-Message CBT for Anxiety

Knoxville, Tennessee
The purpose of the proposed study is to test the feasibility and efficacy of a "anxiety-focused" text-delivered counseling program to reduce anxiety symptoms among young adults (18-25) with elevated anxiety symptoms. We are primarily interested in whether the intervention will reduce anxiety. We have adapted an effective in-person, manualized cognitive behavioral therapy treatment for anxiety (Muñoz et al, 2000) into an 8-week, text-delivered anxiety treatment, named CBT-txt-Anxiety. We will test this with 100 young adults who will be randomized to either CBTtxt-Anxiety or waitlist control condition and assessed at baseline, and at 1- month, 2-months, and 3-months post-baseline.
No Placebo Group

Trial Details

Trial Status:Recruiting
Age:18 - 25

100 Participants Needed

Mindfulness-Based Stress Reduction for Generalized Anxiety Disorder

New York, New York
This trial compares mindfulness meditation and stress education in people with Generalized Anxiety Disorder (GAD). It aims to see how these treatments change brain areas that handle fear and stress. The study also looks at whether men and women respond differently to mindfulness meditation. Brain scans will help understand these changes and predict who might benefit most from mindfulness meditation. Mindfulness-based stress reduction has been shown to effectively reduce symptoms of anxiety and panic in patients with generalized anxiety disorder.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 50

150 Participants Needed

ABBV-932 for Generalized Anxiety Disorder

Grayslake, Illinois
This trial tests a new medication called ABBV-932 to see how it works in the body and if it is safe for healthy adults and those with anxiety or bipolar disorder.

Trial Details

Trial Status:Active Not Recruiting
Age:18 - 65

72 Participants Needed

Virtual Reality Exposure Therapy for Epilepsy-related Anxiety

Toronto, Ontario
The purpose of this randomized control trial is to evaluate the impact of Virtual Reality (VR) Exposure Therapy (ET) on people with epilepsy who experience epilepsy/seizure-specific (ES) interictal anxiety. The main questions it aims to answer are: 1. Can virtual reality exposure therapy (VR-ET) help reduce ES-interictal anxiety in this population? 2. Are the study procedures sufficiently simple for participants to follow? Study Design Summary: * Fourteen (14) participants will be randomized into either an Experimental arm (receiving VR-ET) or Control arm * Participants will be expected to have VR-ET twice a day (5 min/session) for up to 10 days * Participants will complete self-reported questionnaires about anxiety, depression, quality life, and avoidance behaviours at baseline (T0), after completing their VR program (T2), and at a one-month follow-up (T3). * Participants will have a short interview with a researcher after completing their VR program (T2) as well as at a one-month follow-up (T3). Researchers will attempt to answer the study questions based on outcome measures taken at various timepoints and qualitative feedback from interviews.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting

14 Participants Needed

Mindful Self-Compassion for Anxiety and Depression

Washington, District of Columbia
The study will compare 8-week Mindful Self-Compassion training, compared to a control group that does not receive the intervention, on anxiety and depression symptom severity in patients with diagnosed anxiety disorders (generalized anxiety disorder, social anxiety disorder, and panic disorder) or major depressive disorder.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

40 Participants Needed

Cognitive Behavioral Therapy for Anxiety in Autism

Baltimore, Maryland
Anxiety is very common in autistic youth. Recently, an intervention has been created by the investigators to target these symptoms in autistic youth in a community setting. The purpose of this study is to determine the feasibility of implementing this treatment in community care centers.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:7 - 17

60 Participants Needed

CES for Generalized Anxiety Disorder

Chapel Hill, North Carolina
The purpose of this research study is to study cranial electrotherapy stimulation (CES) to determine its effects on symptoms of anxiety in people with generalized anxiety disorder (GAD) between the ages of 18 - 21 years of age.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 21

130 Participants Needed

ITI-1284 for Anxiety

Media, Pennsylvania
This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of ITI-1284 as monotherapy treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD in patients who have had inadequate response to generalized anxiety disorder treatment.

Trial Details

Trial Status:Recruiting

570 Participants Needed

Active on Power

CYB004 for Generalized Anxiety Disorder

Decatur, Georgia
The purpose of this trial is to examine the preliminary clinical efficacy of CYB004 participants with GAD.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 65

36 Participants Needed

Psilocybin for Generalized Anxiety Disorder

Kingston, Ontario
This Phase 2a clinical trial is designed to evaluate the safety, tolerability, and preliminary efficacy of a 3 mg dose of psilocybin oral solution for the treatment of Generalized Anxiety Disorder (GAD). The study consists of three sequential phases: Screening Phase (up to 4 weeks), Open-label Run-in Phase (4 weeks), Double-blind Treatment Phase (4 weeks) Screening Phase During the Screening Visit, participants will provide informed consent and undergo a comprehensive medical evaluation, including an abbreviated psychiatric assessment, to determine eligibility. To qualify, patients must have a clinician-rated Hamilton Anxiety Rating Scale (HAM-A) score ≥14. Additionally, participants must not be on regular anxiolytic treatment or must have discontinued such treatment at least 4 weeks prior to the start of the Open-label Run-in Phase. Open-label Run-in Phase Eligible patients will proceed to the 4-week Open-label Run-in Phase. During this phase, patients will attend four weekly clinic visits, supplemented by weekly remote contacts (via phone or email). At different timepoints during the OL Run-in Phase, participants will complete safety assessments, undergo cognitive testing and EEG and other patient reported outcomes (PROs). Double-blind Treatment Phase Participants who demonstrate a treatment response during the Open-label Phase-defined as a ≥50% reduction in GAD-7 score from baseline-will be randomized 1:1 to receive either psilocybin oral solution or placebo at the Double-blind Baseline Visit. Patients not meeting the response criteria will undergo End-of-Treatment (ET) procedures at this visit. At different timepoints during the DB Treatment Phase, participants will complete safety assessments, undergo cognitive testing and EEG and other patient reported outcomes (PROs). Completion of the End of Treatment (ET) phase will be 2 weeks to further assess safety and PROs.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 60

50 Participants Needed

tACS for Anxiety Disorders

Mount Arlington, New Jersey
This is a clinical research trial exploring the efficacy of non-invasive neuromodulation (NM) intervention in the treatment of anxiety. The NM used in this study consists of 25 minutes of 5 hz transcranial alternating current stimulation (tACS) titrated up to 2mA targeting the anterolateral amygdala across 12 treatment sessions with a 3-4 week time period. The studied population includes patients with the following anxiety disorders: generalized anxiety disorder (GAD), social anxiety disorder (SAD), separation anxiety disorder of childhood, and post-traumatic stress disorder (PTSD). Participants will be randomly assigned to tACS or sham, cross-over, then followed by an optional open-label extension phase.

Trial Details

Trial Status:Recruiting
Age:5+

40 Participants Needed

L-methylfolate for Generalized Anxiety Disorder

Kingston, Ontario
The goal of this feasibility study is to determine the tolerability and safety of add on treatment with L-methylfolate in patients with treatment-resistant generalized anxiety disorder (GAD). The primary objective is to monitor for side effects and other risks associated with the treatment. Secondary objectives are to compare the severity of symptoms, serum levels of folate, vitamin B12, C-reactive protein, homocysteine, tumor necrosis factor alpha and interleukin 6 before and after treatment. Participants will continue with their usual treatment for GAD and receive add on treatment with L-methylfolate 15 mg per day for 8 weeks. All participants will receive the same intervention.
Stay on current meds
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 65

10 Participants Needed

ENX-102 for Generalized Anxiety Disorder

Staten Island, New York
This trial is testing a new medication called ENX-102 to see if it can help people with generalized anxiety disorder by reducing their anxiety symptoms.

Trial Details

Trial Status:Recruiting
Age:18 - 65

280 Participants Needed

Why Other Patients Applied

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

Exercise for Anxiety Disorders

New York, New York
The proposed experimental study will be the first to investigate whether exercise vs. sitting enhances consolidation of extinction learning in adults with high AS and anxiety disorders, and the mechanistic pathways of expectancy, affect, and key stress response markers.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 60

50 Participants Needed

Common Factors Group Psychotherapy for Mental Illness

Birmingham, Alabama
The current research will investigate the impact of general psychotherapy using common factors (i.e., techniques and communication skills that are common to all major forms of psychotherapy) to investigate whether mental health professionals can treat a variety of mental health concerns utilizing this general form of psychotherapy as opposed to specific forms of psychotherapy that may require specific trainings or education.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

30 Participants Needed

Mind-Body Skills Training for Mood Symptoms

White Plains, New York
This trial tests a program that teaches meditation, mindfulness, and relaxation techniques to help medical graduate students manage stress and improve their mood.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

60 Participants Needed

Behavioral Experiments for Generalized Anxiety Disorder

Gatineau, Quebec
Generalized Anxiety Disorder (GAD) is a chronic condition characterized by excessive and uncontrollable worry and anxiety. In adolescents, this condition can seriously impact their development, academic performance, and social relationships. In Canada, 3 to 4% of the population (between 0.9% and 2.7% among adolescents) suffers from GAD at any given time in their lives. These young individuals experience a reduced quality of life and are at risk for numerous medical conditions, as well as additional psychological issues. Research suggests that both pharmacological and psychological approaches are effective in treating GAD in the short term. However, psychological treatments appear to offer the greatest long-term benefits. There are a number of effective psychological treatments for GAD, most of which fall under cognitive-behavioural therapy (CBT) adapted for this age group. In the 1990s, a group of Canadian researchers developed a CBT protocol for GAD that included four components. Data from six clinical trials in adults suggest that one of the four components is particularly important for treatment success: exposing oneself to uncertainty rather than avoiding it in daily life. In other words, learning to tolerate and manage uncertainty seems to be the key to reducing worry and anxiety. Given this discovery, researchers developed a new treatment that exclusively targets intolerance to uncertainty and then adapted it for adolescents: Behavioural Experiments for Intolerance to Uncertainty in Adolescents (EC-IIA). The aim of the current pilot study is to test the effectiveness of EC-IIA in adolescent individuals. A total of 8 participants with a primary diagnosis of GAD will receive EC-IIA and will be evaluated at 4 different times ranging from pre-treatment to a 6-month follow-up. Conditions will be compared in terms of treatment efficacy and mechanisms. Researchers will also examine predictors of change during the 6 months following treatment. The proposed study will produce data on the effectiveness and mechanisms of a treatment for GAD that is less costly, less complex, and easier to disseminate than currently available treatments.
No Placebo Group

Trial Details

Trial Status:Recruiting
Age:14 - 18

8 Participants Needed

Therabot-CALM for Anxiety and Depression

Lebanon, New Hampshire
The goal of this clinical trial is to learn if Therabot-CALM (Cannabis, Anxiety, Low Mood) has acceptability among users and could work to improve the symptoms of persons with cannabis use disorder and anxiety and/or depression. The main question it aims to answer is: What is the usability, feasibility, and acceptability of Therabot-CALM in persons with Cannabis Use Disorder and Anxiety and/or Depression? Participants will * Take a screening questionnaire * Participate in two virtual 1-hour interviews to provide feedback on app design and suggest features. * Engage with Therabot-CALM in a 4-week clinical trial and provide feedback on their app experience in a third virtual interview
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

15 Participants Needed

Exposure Therapy for Child Anxiety

Riverside, Rhode Island
There is strong evidence that cognitive behavioral therapy (CBT) with exposure is the preferred treatment for youth with anxiety disorders, but outpatient services that provide this type of treatment are limited. Even for those who do have access to anxiety-specific treatment, a traditional outpatient model of treatment delivery may not be suitable. Among the numerous logistical barriers to treatment access and response is the inability to generalize treatment tools to settings outside of the office. Patient-centered (home-based or telehealth; patient-centered telehealth closed as of 5/1/21) treatment models that target symptoms in the context in which they occur could be more effective, efficient, and accessible for families. The present study aims to compare the efficacy, efficiency, and feasibility of patient centered home-based CBT and patient centered telehealth CBT with a traditional office-based model of care. The question proposed, including proposed outcomes, have been generated and developed by a group of hospital, payer, patient and family stakeholders who will also contribute to the iterative process of protocol revision. The investigators anticipate 379 anxious youth to be randomized to receive outpatient treatment using telehealth (patient-centered telehealth closed as of 5/1/21), home-based services, or treatment as usual using a traditional outpatient model. Results of this study are expected to provide evidence for the efficacy and efficiency of patient-centered treatment, as well as increase treatment access and family engagement in the treatment process.
No Placebo Group

Trial Details

Trial Status:Recruiting
Age:5 - 18

379 Participants Needed

Internet-Based Cognitive Behavioral Therapy for Alcoholism

Minneapolis, Minnesota
This project is designed to determine if a computer-delivered cognitive-behavioral treatment can improve the otherwise poor alcohol use disorder treatment outcomes for individuals with a co-occurring anxiety disorder. In the past, the investigators showed that this treatment does improve outcomes for these individuals when delivered by a therapist. If the present work shows that the computer-delivered version is also effective, it would provide an inexpensive program with virtually unlimited scalability to enable access to the treatment by many more individuals than is currently the case.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65

256 Participants Needed

Psychological Treatment for Intrusive Thoughts

Boston, Massachusetts
The investigators are conducting this study to learn more about the cognitive and attentional processes among individuals with three types of repetitive negative thinking (RNT): mental rituals (as seen in obsessive compulsive disorder, OCD), worries (as seen in generalized anxiety disorder, GAD), and ruminations (as seen in major depressive disorder, MDD). Specifically, the investigators are studying whether psychological treatment can help people with RNT who have trouble stopping unwanted thoughts and shifting their attention.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Age:18 - 60

87 Participants Needed

Cognitive Behavioral Therapy for Depression

Boston, Massachusetts
To examine the effectiveness and clinical care outcomes of cognitive-behavioral therapy interventions at Massachusetts General Hospital (MGH).
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

250 Participants Needed

Transcranial Magnetic Stimulation for Mental Illness

Boston, Massachusetts
Participants will receive Transcranial Magnetic Stimulation (TMS) at a random location in the left prefrontal cortex, excluding sites that are potentially unsafe. Extensive behavioral testing will be conducted to determine which behaviors are modulated by stimulating which circuits.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65

180 Participants Needed

12

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Generatlized Anxiety Disorder clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Generatlized Anxiety Disorder clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Generatlized Anxiety Disorder trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Generatlized Anxiety Disorder is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Generatlized Anxiety Disorder medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Generatlized Anxiety Disorder clinical trials?

Most recently, we added Virtual Reality Glasses for Procedural Anxiety, Psilocybin for Generalized Anxiety Disorder and ABBV-932 for Generalized Anxiety Disorder to the Power online platform.

What do the "Power Preferred" and "SuperSite" badges mean?

We recognize research clinics with these awards when they are especially responsive to patients who apply through the Power online platform. SuperSite clinics are research sites recognized for a high standard of rapid and thorough follow-up with patient applicants. Meanwhile, Power Preferred clinics are the top 20 across the entire Power platform, recognized for their absolute top patient experience.

Which clinics have received Power Preferred and SuperSite awards recruiting for Generatlized Anxiety Disorder trials?

The Generatlized Anxiety Disorder clinics currently recognized as Power Preferred are: Neuro-Behavioral Clinical Research, Inc. Site #115 in North Canton, Ohio Center for Emotional Fitness Site #104 in Cherry Hill, New Jersey CenExel ACMR in Atlanta, Georgia Berman Clinical (#143) in New York, New York Bioscience Research in Mt Kisco, New York Neurobehavioral Research, Inc. Site #100 in Cedarhurst, New York Adams Clinical in Watertown, Massachusetts Copley Clinical Research in Boston, Massachusetts IMA Phoenix (#142) in Phoenix, Arizona Anderson Clinical Research in Redlands, California Anderson Clinical Research in Redlands, California Excell Research, Inc. Site #106 in Oceanside, California Excell Research Inc in Oceanside, California Excell Research Inc in Oceanside, California Sunwise Clinical Research, LLC. in Walnut Creek, California The Generatlized Anxiety Disorder clinics currently recognized as SuperSites are: The Medical Research Network, L.L.C Site #111 in New York, New York CenExel iResearch Savannah in Savannah, Georgia Clinical Neuroscience Solutions, Inc. in Jacksonville, Florida Sooner Clinical Research Site#105 in Oklahoma City, Oklahoma CenExel RCA (Research Centers of America) in Hollywood, Florida California Neuroscience Research, LLC in Sherman Oaks, California CenExel Collaborative Neuroscience Research Site #113 in Torrance, California

Popular Searches

By Condition

Depression Clinical Trials

Anxiety Clinical Trials

Schizophrenia Clinical Trials

ADHD Clinical Trials

Bipolar Disorder Clinical Trials

Multiple Sclerosis Clinical Trials

Autism Clinical Trials

Treatment Resistant Depression Clinical Trials

Borderline Personality Disorder Clinical Trials

Social Anxiety Disorder Clinical Trials

Parkinson's Disease Clinical Trials

Alzheimer's Disease Clinical Trials

By Location

Clinical Trials in California

Clinical Trials in Florida

Clinical Trials in Texas

Clinical Trials in New York

Clinical Trials in Ohio

Clinical Trials in Illinois

Clinical Trials in Pennsylvania

Clinical Trials in Michigan

Clinical Trials in North Carolina

Clinical Trials in Massachusetts

Clinical Trials in Missouri

Clinical Trials in Minnesota

Other People Viewed

By Subject

Top Anxiety Disorder Clinical Trials

Top Social Anxiety Disorder Clinical Trials

Top Eating Disorder Clinical Trials

Top Bipolar Disorder Clinical Trials

Top Panic Disorder Clinical Trials

Top Sleep Disorder Clinical Trials

Top Major Depressive Disorder Clinical Trials

Top Obsessive-Compulsive Disorder Clinical Trials

Top Borderline Personality Disorder Clinical Trials

Top Anxiety Clinical Trials

Top Social Anxiety Clinical Trials

Top Binge Eating Disorder Clinical Trials

By Trial

Exposure Therapy for Social Anxiety Disorder

CES for Generalized Anxiety Disorder

Online Psychotherapy for Anxiety and Depression in Cancer Patients

Ashwagandha for Anxiety

Drug Therapy for Anxiety

Virtual Reality Therapy for Anxiety

CALM Intervention for Childhood Anxiety Disorder

ITI-1284 for Anxiety

Lavender Aromatherapy for Anxiety During Skin Cancer Surgery

Virtual Therapy for Alcohol Consumption and Opioid Use Disorder

Music Therapy for Anxiety in Blood Cancer Procedures

Buprenorphine/Naloxone for Opioid Use Disorder

Related Searches

Top Hepatitis-b Clinical Trials

Top Acute-lymphoblastic-leukemia Clinical Trials

Top Infectious-disease Clinical Trials

Top Treatment for Cannabidiol Clinical Trials

Top Treatment for Cannabis Clinical Trials

Ketorolac + Lidocaine for Pain Relief During Hysteroscopy

Mindfulness and HIIT for Executive Function in Children

Subretinal Injection for Leber Congenital Amaurosis

Guanfacine for Alcohol Use Disorder

Drug Resistance Research for Osteosarcoma

Motivational Interviewing for Hearing Loss

Enhanced Recovery After Surgery for Appendicitis

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial